Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s diseaseClear and ...

The average one-year price target for ProMIS Neurosciences (NasdaqCM:PMN) has been revised to $137.06 / share. This is an increase of 2,288.89% from the prior estimate of $5.74 dated November 14, 2025 ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS ...

ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...

ProMIS Neurosciences, a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a purchase agreement to issue approximately $2.4 ...

ProMIS Neurosciences shares surged after the company said the Food and Drug Administration granted a fast-track designation to the company's in-development treatment for Alzheimer's disease. Shares ...

ProMIS Neurosciences (NASDAQ:PMN) announced in vitro preclinical data that showed differentiation of PMN310 from other amyloid-beta-directed antibodies at the International Conference on Alzheimer’s ...

Purpose This study investigated the PROMIS Self-Efficacy Measure for Managing Chronic Conditions (PROMIS-SE) domain distributions and examined the factor structure of the PROMIS-SE. Methods A total of ...

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics ...